Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 protein expression in leukemias

S Paydas1

  • 1Faculty of Medicine, Department of Oncology, Cukurova University, Balcali Adana, Turkey.

Acta Oncologica (Stockholm, Sweden)
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy.

European review for medical and pharmacological sciences·2023
Same author

Comparison of different cyclin-dependent kinase inhibitors and KI-67 levels on survival and toxicity in breast cancer treatment.

European review for medical and pharmacological sciences·2023
Same author

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.

Cancer chemotherapy and pharmacology·2018
Same author

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Bone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients.

Transplantation proceedings·2016
Same author

Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?

Annals of oncology : official journal of the European Society for Medical Oncology·2016

p53 protein expression was found in 26% of leukemia patients. Abnormalities in p53 may drive leukemogenesis and the development of aggressive cancer clones in chronic leukemias.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • The p53 protein is a critical tumor suppressor.
  • Altered p53 expression is implicated in various cancers, including leukemia.
  • Understanding p53's role in leukemogenesis is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the expression of p53 protein in different types of leukemia.
  • To correlate p53 expression with specific leukemia subtypes and clinical progression.

Main Methods:

  • Immunohistochemistry was used to detect p53 protein expression.
  • The study included 58 patients diagnosed with various forms of leukemia.

Main Results:

  • p53 protein expression was observed in 26% of all leukemia cases studied.

Related Experiment Videos

  • Specific positive rates were noted for acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and acute lymphoid leukemia (ALL).
  • In patients with p53 expression, advanced disease stages were observed, including RAEB-transformation in AML, Richter's syndrome in CLL, and accelerated phase in CML.

    • Conclusions:

    • p53 protein abnormalities appear to play a significant role in the development of leukemia.
    • These abnormalities may also contribute to the evolution of more aggressive clones in chronic leukemias.